Treatment goals in psoriasis;Therapieziele bei der behandlung der psoriasis

JDDG - Journal of the German Society of Dermatology

Volumn 5, Issue 7, 2007, Pages 566-574

  Reich, Kristian ^a,c   Mrowietz, Ulrich ^b  

^a Dermatologikum Hamburg ^*  (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c Dermatologikum Hamburg   (Germany)

Author keywords

Biologics; Guidelines; Psoriasis; Therapy

Indexed keywords

ADALIMUMAB; ALCOHOL; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CICLORAL HEXAL; COLECALCIFEROL; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMADERM; IMMUNOSPORIN; INFLIXIMAB; INSULIN; LANTAREL; LEFLUNOMIDE; METEX; METHOTREXATE; UNCLASSIFIED DRUG;

ALCOHOL ABUSE; COST OF ILLNESS; DEPRESSION; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; HYPERTENSION; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SHORT FORM 36; SUICIDAL BEHAVIOR; ULTRAVIOLET B RADIATION;

DERMATOLOGIC AGENTS; GERMANY; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34447249510     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2007.06343.x     Document Type: Review

References (33)

1. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B. S3-Leitlinie zur Therapie der Psoriasis vulgaris. J Dtsch Dermatol Ges. 2006 Nov; 4(s2): S1-S126.
2. Dubertret L, Mrowietz U, Ranki A, van de Kerkhof PC, Chimenti S, Lotti T, Schafer G. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006 Oct; 155(4): 729-736.
3. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001 Mar; 137(3): 280-284.
4. Zschocke I, Hammelmann U, Augustin M. Therapeutic benefits in dermatological therapy. Evaluation of therapy from the physician's und patient's perspective in psoriasis and atopic dermatitis. Hautarzt 2005 Sep;56(9): 839-842.
5. Fleischer AB Jr, Feldman SR, Rapp SR. The magnitude of skin disease in the United States. Dermatol Clin. 2000 Apr; 18(2): xv-xxi.
6. Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN. Suicidal ideation in psoriasis. Int J Dermatol. 1993 Mar; 32(3): 188-190.
7. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3): 210-216.
8. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995 Feb; 132(2): 236-244.
9. Augustin M, Zschocke I, Seidenglanz K, Lange S, Schiffler A, Amon U. Validation and clinical results of the FLQA-d, a quality of life questionnaire for patients with chronic skin diseases. Dermatol Psychosom. 2000; 1: 12-17.
10. Manner K. Methodenentwicklung und klinische Anwendung von Willingness-to-pay und Conjoint-Analyse als Parameter der Prä ferenzenbildung bei Psoriasis vulgaris. Unveröffentlichte medizinische Dissertation. Freiburg 2005.
11. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999 Sep; 41(3 Pt 1): 401-407.
12. Schiffner R, Schiffner-Rohe J, Gerstenhauer M, Hofstadter F, Landthaler M, Stolz W. Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients? Br J Dermatol. 2003 Jun; 148(6): 1153-1160.
13. Sohn S, Schoeffski O, Prinz J, Reich K, Schubert E, Waldorf K, Augustin M. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006; 212(2): 137-144
14. Augustin M, Zschocke I, Lange S, Seidenglanz K, Amon U. Quality of life in skin diseases: methodological and practical comparison of different quality of life questionnaires in psoriasis and atopic dermatitis. Hautarzt. 1999 Oct; 50(10): 715-722.
15. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol. 2005 Oct; 125(4): 659-664.
16. Crown WH, Bresnahan BW, Orsini LS, Kennedy S, Leonardi C. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin. 2004 Dec; 20(12): 1929-1936.
17. Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Ekbom A, Stahle-Backdahl M. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004; 19(3): 225-230.
18. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006 Dec; 298(7): 321-328.
19. Gupta MA, Gupta AK. Psoriasis and sex: a study of moderately to severely affected patients. Int J Dermatol. 1997 Apr; 36(4): 259-262.
20. Reynoso-von Drateln C, Martinez-Abundis E, Balcazar-Munoz BR, Bustos-Saldana R, Gonzalez-Ortiz M. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol. 2003 Jun; 48(6): 882-885.
21. Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005 Jul; 32(7): 1213-1218.
22. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005 Mar; 64 Suppl 2: ii14-7. Review.
23. Krueger K, Augustin M, Rauch C, Reich K. Prevalence and clinical manifestations of arthritis in a daily practice psoriasis population - a prospective observational study in Germany. Ann Rheum Dis, July 2006, Vol 65, Suppl II, 531, Abs SAT0265.
24. Mrowietz U, Elder JT, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res. 2006 Dec; 298(7): 309-319.
25. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE; Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005 Oct 15-21; 366(9494): 1367-1374.
26. Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, Shear NH, Papp KA; CLEAR Multinational Study Group. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol. 2006 Jul; 155(1): 170-181.
27. Mössner R, Reich K. Infliximab in the treatment of psoriasis. Expert Rev Dermatol 2006; 1 (4): 515-526.
28. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005 May; 152(5): 861-867. Review.
29. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005 Jan; 141(1): 31-38.
30. Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol. 2005 Dec; 153(6): 1192-1199.
31. Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol. 2006 Jun; 154(6): 1161-1168.
32. McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis. 2004 Feb; 63(2): 162-169.
33. Kragballe K, Austad J, Barnes L, Bibby A, de la Brassinne M, Cambazard F, Fleming C, Heikkila H, Jolliffe D, Peyri J, Svensson A, Toole J, Wozel G. A 52-week randomized safety study of a calcipotriol /betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treat-ment of psoriasis vulgaris. Br J Dermatol. 2006 Jun; 154(6): 1155-1160.